US Starts Clinical Trial for mRNA Nipah Virus Vaccine
The experimental Nipah virus vaccine (mRNA-1215) is manufactured by Moderna, Inc. and was developed in collaboration with NIAID’s Vaccine Research ...
The experimental Nipah virus vaccine (mRNA-1215) is manufactured by Moderna, Inc. and was developed in collaboration with NIAID’s Vaccine Research ...
A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes ...
NIAID supports Biodefense and Emerging Infectious Diseases Research Infrastructure as a key component of our mission to safely and effectively ...
Albany Medical College scientists have been awarded a $3 million, five-year federal grant to develop a vaccine that could protect ...
The Bacterial and Viral Bioinformatics Resource Center (BV-BRC), an initiative funded by the National Institute of Allergy and Infectious Diseases (NIAID), ...
In 2021, Bucknell University biology professors DeeAnn Reeder and Ken Field received a $2.9 million grant from the National Institute ...
The findings point to the need for mRNA-1273 booster vaccination to sustain high-level and rapid protection in the lung and ...
The University of Tennessee Health Science Center has been awarded $3.2 million from the National Institute of Allergy and Infectious ...
The awards are intended to fuel vaccine research for a diverse family of coronaviruses, with a primary focus on potential ...
Reformulating influenza vaccines annually against dominant circulating strains leads to variable protective efficacy and is unlikely to protect against novel ...
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting input from the radiation biology and microbiome research communities ...
NIH Launches Clinical Trial of Universal Influenza Vaccine Candidate A first-in-human, Phase 1 trial assessing the safety and immunogenicity of ...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is soliciting research ...
New research shows pigs could serve as amplifying hosts for Reston ebolavirus. Reston ebolavirus (RESTV) should be considered a livestock ...
The National Institute of Allergy and Infectious Diseases (NIAID) is seeking statements of capability or interest from parties interested in ...
With multiple promising SARS-CoV-2 vaccine candidates now under development, the National Institute of Allergy and Infectious Diseases (NIAID) is looking ...
The National Institutes of Health is fast-tracking funding for development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus ...
The new Centers for Research in Emerging Infectious Diseases (CREID) — comprised of 10 research centers and a coordinating center — is ...
An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well ...
A Special Emphasis Panel of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of ...